Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

Marc Ychou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7378-9469; OpenAlex author ID A5014415808. Sources: ClinicalTrials.gov.

Their work

Papers
17 (first author 0, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
51
Papers, trials and grants by year

2008: 1 trial · 2009: none · 2010: none · 2011: 3 papers · 2012: none · 2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 17

  1. Is survival influenced by metastatic site in synchronous metastatic pancreatic adenocarcinoma (PDAC)? A prospective real-world BACAP study. Co-author DOI 10.1016/j.esmogo.2025.100144↗
  2. GABRINOX-2 protocol: a French, prospective, multicentre, randomised phase II trial evaluating gemcitabine/nab-paclitaxel followed by FOLFIRINOX versus FOLFIRIN… Last author DOI 10.1136/bmjopen-2025-104228↗
  3. Predictive genomic and transcriptomic analysis on endoscopic ultrasound-guided fine needle aspiration materials from primary pancreatic adenocarcinoma: a prosp… Co-author DOI 10.1016/j.ebiom.2024.105373↗
  4. Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-Wo… Co-author DOI 10.1093/oncolo/oyac217↗
  5. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  6. Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcino… Co-author DOI 10.1002/ijc.33225↗
  7. Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinica… Co-author DOI 10.1016/j.esmoop.2021.100318↗
  8. Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. Co-author DOI 10.1053/j.gastro.2019.12.009↗
  9. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.1056/nejmoa1809775↗
  10. An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.12761↗
  11. Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "TH… Co-author DOI 10.18632/oncotarget.3473↗
  12. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Co-author DOI 10.1016/j.ctrv.2013.04.004↗
  13. The role of the FOLFIRINOX regimen for advanced pancreatic cancer. Co-author DOI 10.1007/s11912-012-0290-4↗
  14. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomize… Co-author DOI 10.1200/jco.2012.44.4869↗
  15. [Histologic assessment of treatment effect of preoperative chemoradiation in patients presenting with resectable pancreatic adenocarcinoma]. Co-author DOI 10.1016/j.canrad.2010.06.019↗
  16. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. Co-author DOI 10.1056/nejmoa1011923↗
  17. Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II tr… Co-author DOI 10.1186/1748-717x-6-124↗

Trials 1

  1. Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine Principal investigator NCT00923299↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eric Assénat · 6 shared papers, 2011–2025 · strength 0.66
  2. Fabienne Portales · 4 shared papers, 2015–2025 · strength 0.59
  3. Thierry Conroy · 6 shared papers, 2011–2023 · strength 0.36
  4. Christelle de la Fouchardière · 2 shared papers, 2011–2021 · strength 0.15
  5. Susan Elaine Bates · 1 shared paper, 2023 · strength 0.15
  6. Yvonne M. Saenger · 1 shared paper, 2023 · strength 0.15
  7. Keith Magnus Sigel · 1 shared paper, 2023 · strength 0.15
  8. Gayle Jameson · 1 shared paper, 2023 · strength 0.15
  9. Celine Yeh · 1 shared paper, 2023 · strength 0.15
  10. Rachael Ann Safyan · 1 shared paper, 2023 · strength 0.15
  11. Elizabeth M. Hecht · 1 shared paper, 2023 · strength 0.15
  12. John A. Chabot · 1 shared paper, 2023 · strength 0.15
  13. Gulam Abbas Manji · 1 shared paper, 2023 · strength 0.15
  14. Tito Fojo · 1 shared paper, 2023 · strength 0.15
  15. Daniel D. Von Hoff · 1 shared paper, 2023 · strength 0.15
  16. Michel Pierre Ducreux · 4 shared papers, 2011–2014 · strength 0.14
  17. Thibault Mazard · 1 shared paper, 2021 · strength 0.13
  18. Thibaut Mazard · 1 shared paper, 2021 · strength 0.11
  19. S. Gourgou-Bourgade · 3 shared papers, 2011–2016 · strength 0.11
  20. Jean‐Luc Raoul · 3 shared papers, 2011–2018 · strength 0.11
  21. Antoine Adenis · 3 shared papers, 2011–2013 · strength 0.08
  22. Jean‐Baptiste Bachet · 2 shared papers, 2011–2018 · strength 0.07
  23. Julien Péron · 1 shared paper, 2016 · strength 0.06
  24. Marc E Buyse · 1 shared paper, 2016 · strength 0.06
  25. Patrick Rat · 1 shared paper, 2018 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.